MedTrace Logo

Neo-adjuvant Chemotherapy With Letrozole in Patients With Estrogen Receptor Positive/HER-2 Negative Breast Cancer

NCT03497702 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2018-04-13

No results posted yet for this study

Summary

This is an exploratory interventional study that initiates chemotherapy with letrozole in patients with estrogen receptor positive/HER2-negative breast cancer preoperably.

Conditions

Interventions

DRUG

Doxorubicin

60mg/m2 IV every 3 weeks for 4 cycles

DRUG

Cyclophosphamide

600mg/m2 IV every 3 weeks for 4 cycles

DRUG

Docetaxel

75mg/m2 IV every 3 weeks for 4 cycles

DRUG

Letrozole

2.5 mg once daily preoperably

DRUG

leuprorelin

3.75 mg SC every 4 weeks for premenopausal patients

Sponsors & Collaborators

  • National Cancer Center, Korea

    lead OTHER_GOV

Principal Investigators

  • Keun Seok Lee, MD, PhD · National Cancer Center

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
19 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-05-08
Primary Completion
2023-11-30
Completion
2024-01-31

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03497702 on ClinicalTrials.gov